Genesis Unicorn Capital Corp.
We intend to focus our search on the intersection of the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. We intend to capitalize on the ability of our management team to identify promising opportunities at the intersection of the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. Our objective is to focus on middle market and emerging growth businesses operating with a total enterprise value from $200 million to $1 billion, which companies may be located throughout the world except for an entity or business with its principal or a majority of its business operations (either directly or through any subsidiaries) in the People’s Republic of China, (including Hong Kong and Macau. (Incorporated in Delaware)
Although our sponsor, Genesis Unicorn Capital, and certain members of our Board of Directors and management have significant business ties to or are based in the People’s Republic of China or Hong Kong, we have determined that because of uncertainties in the regulatory climate in these jurisdictions, and the potential for future governmental actions which might unfavorably impede future operations, we will not consider or undertake a business combination with an entity or business with its principal or a majority of its business operations (either directly or through any subsidiaries) in the People’s Republic of China (including Hong Kong and Macau).
Our principal office is located in the United States. Our CEO is a United States citizen and located in the United States. Our sponsor is a Delaware limited liability company. Additionally, the two Co-Chairs of our Board of Directors are not residents of or located in China, Hong Kong or Macau.
Dr. Adeoye (Oye) Olukotun, our Chief Executive Officer, has over 35 years in the pharmaceutical industry. He is a Mayo Clinic trained cardiologist who currently serves as the Chief Executive Officer of CR Strategies, LLC, a position he has held since April 2000. He previously served as the Chief Executive Officer and President of Epigen Pharmaceuticals, Inc. from June 2014 to March 2017, and Vice Chairman of CardioVax, Inc., from January 2013 to April 2016. Dr. Olukotun served as the Chief Medical Officer of VIA Pharmaceuticals Inc. from 2004 to 2008. He spent the first 20 years of his career in roles of increasing responsibility in clinical development at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others.
(Note: Genesis Unicorn Capital Corp. priced its SPAC IPO on Feb. 14, 2022, in line with the terms in its prospectus: 7.5 million units at $10 each to raise $75 million.)
|Address||281 Witherspoon Street, Suite 120 Princeton, NJ, 08540|
|Phone Number||(609) 466-0792|
|View Prospectus:||Genesis Unicorn Capital Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$75.0 mil|
|Manager / Joint Managers||EF Hutton|
|Expected To Trade:||2/15/2022|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|